Ethnic differences in the distribution of CYP3A5 gene polymorphisms

Xenobiotica

Volumn 36, Issue 12, 2006, Pages 1191-1200

  Quaranta, S ^a,b   Chevalier, D ^a   Allorge, D ^a   Lo Guidice, J M ^a   Migot Nabias, F ^c,d   Kenani, A ^e   Imbenotte, M ^a   Broly, F ^a   Lacarelle, B ^b   Lhermitte, M ^a  

^a UNIV LILLE   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Centre International de Recherche Médicales de Franceville   (France)

^d UR010   (Tunisia)

^e UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

Allele frequency; CYP3A5; Ethnic differences; Polymorphisms

Indexed keywords

CYTOCHROME P450 3A5;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; ENZYME METABOLISM; ENZYME SUBSTRATE; ETHNIC DIFFERENCE; FRANCE; GABON; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; NULL ALLELE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUNISIA;

ALLELES; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FRANCE; GABON; GENE FREQUENCY; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUNISIA;

EID: 33845611851     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250600944300     Document Type: Article

References (28)

1. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, Beaune P, et al. 2004. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clinical Pharmacology and Therapy 75:422-433.
2. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV, et al. 1989. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. Journal of Biology and Chemistry 264:10388-10395.
3. Cauffiez C, Pottier N, Tournel G, Lo-Guidice JM, Allorge D, Chevalier D, Migot-Nabias F, Kenani A, Broly F. 2005. CYP2A13 genetic polymorphism in French Caucasian, Gabonese and Tunisian populations. Xenobiotica 35:661-669.
4. Chevalier D, Allorge D, Lo-Guidice JM, Cauffiez C, Lepetit C, Migot-Nabias F, Kenani A, Lhermitte M, Broly F. 2002. Sequence analysis, frequency and ethnic distribution of VNTR polymorphism in the 5′-untranslated region of the human prostacyclin synthase gene (CYP8A1). Prostaglandins and Other Lipid Mediators 70:31-37.
5. Cholerton S, Daly AK, Idle JR. 1992. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends in Pharmacology Science 13:434-439.
6. Chou FC, Tzeng SJ, Huang JD. 2001. Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metabolism and Disposition 29:1205-1209.
7. Chowbay B, Zhou S, Lee EJ. 2005. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: Experience in Singapore. Drug Metabolism Review 37:327-378.
8. Daly AK. 2006. Significance of the minor cytochrome P450A isoforms. Clinical Pharmacokinetics 45:13-31.
9. Eichelbaum M, Ingelman-Sundberg M, Evans WE. 2006. Pharmacogenomics and individualized drug therapy. Annual Review of Medicine 57:119-137.
10. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. 2002. Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359:30-36.
11. Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB. 2003. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. Journal of Applied Physiology 95:1297-1300.
12. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P. 2004. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147-154.
13. Hesselink DA, Van Schaik RH, Van der Heiden IP, Van der Werf M, Gregoor PJ, Lindemans J, Weimar W, Van Gelder T. 2003. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clinical Pharmacology and Therapy 74:245-254.
14. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. 2001. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
15. Jounaidi Y, Hyrailles V, Gervot L, Maurel P. 1996. Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein? Biochemistry and Biophysics Research Communications 221:466-470.
16. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, Gerber N. 1998. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metabolism and Disposition 26:552-561.
17. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 27:383-391.
18. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, Mohrenweiser HW, Goldstein JA. 2003. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 13:461-472.
19. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW. 2004. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. American Journal of Transplantation 4:914-919.
20. Nebert DW, Menon AG. 2001. Pharmacogenomics, ethnicity, and susceptibility genes. Pharmacogenomics Journal 1:19-22.
21. Quaranta S, Chevalier D, Bourgarel-Rey V, Allorge D, Solas C, Lo-Guidice JM, Sampol-Manos E, Vacher-Coponat H, Moal V, Broly F, et al. 2006. Identification by single-strand conformational polymorphism analysis of known and new mutations of the CYP3A5 gene in a French population. Toxicology Letters 164:177-184.
22. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, Roger M. 2005. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metabolism and Disposition 33:884-887.
23. Saeki M, Saito Y, Nakamura T, Murayama N, Kim SR, Ozawa S, Komamura K, Ueno K, Kamakura S, Nakajima T, et al. 2003. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Human Mutation 21:653-659.
24. Schuetz JD, Beach DL, Guzelian PS. 1994. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
25. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK. 2003. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76:1233-1235.
26. Wojnowski L, Turner PC, Pedersen B, Hustert E, Brockmoller J, Mendy M, Whittle HC, Kirk G, Wild CP. 2004. Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 14:691-700.
27. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, Molowa DT, Vandenbranden M. 1990. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Molecular Pharmacology 38:207-213.
28. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. 2004. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272.